|
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective
therapy for patients with chronic myelogenous leukemia (CML). Despite durable
responses in most chronic phase patients, relapses have been observed and are
much more prevalent in patients with advanced disease. The most common mechanism
of acquired imatinib resistance has been traced to Bcr-Abl kinase domain
mutations with decreased imatinib sensitivity.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
